Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences T (JAGLX)

75.49 +0.71 (+0.95%)
At close: 8:01 PM EST

Top 10 Holdings (42.01% of Total Assets)

SymbolCompany% Assets
LLY
Eli Lilly and Company 8.92%
UNH
UnitedHealth Group Incorporated 6.72%
NOVO-B.CO
Novo Nordisk A/S 5.33%
AZN.L
AstraZeneca PLC 4.00%
ABBV
AbbVie Inc. 3.61%
AMGN
Amgen Inc. 3.20%
MRK
Merck & Co., Inc. 2.79%
SAN.PA
Sanofi 2.63%
BSX
Boston Scientific Corporation 2.46%
NVS
Novartis AG 2.34%

Sector Weightings

Overall Portfolio Composition (%)

Cash 0.49%
Stocks 98.79%
Bonds 0.01%
Others 0.42%
Preferred 0.26%
Convertible 0.03%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average JAGLX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.18 5.28
Price/Sales 0.35 2.06
Price/Cashflow 0.04 17.54
Median Market Cap 86,861.57 34,862.81
3 Year Earnings Growth 3.96 32.48

Bond Holdings

Performance & Risk

YTD Return 8.82%
5y Average Return 10.14%
Rank in Category (ytd) 16
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.74
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 5.5B
YTD Return 12.67%
Yield 0.06%
Morningstar Rating
Inception Date Jul 06, 2009

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers